News on molecular diagnostics, pharmacogenomics tests for coronary artery disease, congenital heart defects, and more.
The Finnish diagnostics company is working to expand US and European sales of its ceramide lipid-based cardiovascular risk assessment assay, CERT.
The partners anticipate developing tests that analyze clusters of biomarkers to detect cardiovascular disease, kidney disease, liver cancer, and other diseases.
Galaxy has licensed IP from Proteome Sciences for the development of a test for the diagnosis and timing of stroke onset to help inform treatment decisions.
The tests are designed to detect genetic variations including SNPs, insertion-deletions, copy number variations, and variations in segmental duplications.
Clinicians need to understand higher-sensitivity troponin assays will detect longer-term cardiac injury as well as acute conditions, experts say.
